An international collaboration has led to the development of a comprehensive tool [CLL‐IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL‐IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2‐microglobulin plasma levels, clinical stage, and age. CLL‐IPI provides the means to stratify CLL patients in the daily clinical practice (Table S1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL‐IPI on progression‐free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first‐line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.
Gentile, M., Shanafelt, T. D., Mauro, F. R., Reda, G., Rossi, D., Laurenti, L., Del Principe, M. I., Cutrona, G., Angeletti, I., Coscia, M., Herishanu, Y., Chiarenza, A., Molica, S., Ciolli, S., Goldschmidt, N., Angrilli, F., Giordano, A., Rago, A., Bairey, O., Tripepi, G., Chaffee, K. G., Sameer, P. A., Vigna, E., Zirlik, K., Shvidel, L., Innocenti, I., Recchia, A. G., Di Raimondo, F., Del Poeta, G., Cortelezzi, A., Neri, A., Ferrarini, M., Gaidano, G., Kay, N. E., Polliack, A., Foa, R., Morabito, F., Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment, <<EUROPEAN JOURNAL OF HAEMATOLOGY>>, 2018; (24): N/A-N/A. [doi:10.1111/ejh.13149] [http://hdl.handle.net/10807/135006]
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment
Laurenti, Luca;Innocenti, Idanna;Foa, Robin;
2018
Abstract
An international collaboration has led to the development of a comprehensive tool [CLL‐IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL‐IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2‐microglobulin plasma levels, clinical stage, and age. CLL‐IPI provides the means to stratify CLL patients in the daily clinical practice (Table S1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL‐IPI on progression‐free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first‐line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
